Developer docs
API playgroundTry for free, no card

Search company profiles

Biolidics

Full company profile

uuid0003p97

Namestring
Biolidics
Legal namestring
Embracing Future Holdings Limited
Websiteurl
biolidics.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Biolidics is the operating brand of Embracing Future Holdings Limited (EFH), a Singapore-incorporated, SGX-listed (ticker: 8YY) medical device company founded in 2009 that develops and commercializes the ClearCell FX1 System, a fully automated IVD medical device for label-free separation and enrichment of circulating tumor cells (CTCs) from blood. The system is built around the proprietary, patented CTChip FR1 microfluidic biochip, which isolates wholly intact and viable CTCs in liquid suspension that can be transferred to standard laboratory formats such as glass slides and microtiter plates for integration with routine pathology workflows. The company is headquartered at 122 Emerald Hill Road, Singapore, and serves pathology laboratories and oncology healthcare providers engaged in cancer diagnostics, liquid biopsy, and CTC research.

The company monetizes through hardware sales of the ClearCell FX1 System under a quote-based pricing model that is not publicly disclosed. Its go-to-market combines direct enterprise sales via a Request-for-Quotation channel on the corporate website with marketplace distribution through LabX, enabling access to both large laboratories and smaller research buyers. Beyond the oncology diagnostics franchise, EFH has publicly disclosed a strategic intent to diversify into technology-enabled lifestyle businesses, including Multi-Channel Networks, live streaming social e-commerce, and Esports-related operations. The company has raised approximately $11.7M in disclosed funding across a 2013 Series A led by Vertex Ventures and a 2018 round, and acquired Biomedical Laboratory in March 2020 for approximately $2.6M.

Short descriptiontext

Biolidics (Embracing Future Holdings Limited, SGX: 8YY) is a Singapore-based medical device company that develops and commercializes the ClearCell FX1 System, an FDA-cleared IVD device using its patented CTChip FR1 microfluidic biochip to enrich circulating tumor cells from blood for pathology laboratories and oncology researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
circulating tumor cell enrichment, liquid biopsy diagnostics, microfluidic biochip technology, IVD medical devices, cancer diagnostics
Industry2 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cancer Diagnostics Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Sale of the ClearCell FX1 System, a fully automated IVD medical device for CTC enrichment. Revenue generated through direct sales to laboratories and healthcare facilities, as well as through marketplace distribution.

ebfholdings.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
Pricing details1 tier
1Quote-based pricing for ClearCell FX1 System
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing available upon request through the Request for Quotation process on the company website. Product also available on LabX marketplace.

ebfholdings.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Biolidics develops and commercializes the ClearCell FX1 System, a fully automated in-vitro diagnostic (IVD) medical device that separates and enriches circulating tumor cells (CTCs) from blood samples using a patented microfluidic biochip (CTChip FR1). The system enables label-free, viable and intact CTC isolation that can be transferred to standard laboratory formats such as glass slides and microtiter plates for downstream pathology and oncology workflows.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Biolidics offers a focused diagnostic product portfolio centered on the ClearCell® FX1 System, a fully automated IVD medical device for circulating tumor cell (CTC) enrichment. The system incorporates the proprietary CTChip® FR1 microfluidic biochip to achieve label-free separation of viable and intact cancer cells from blood samples. The isolated CTCs are collected in liquid suspension and can be transferred to standard laboratory formats such as glass slides and microtiter plates for integration with routine pathology workflows.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

LabX serves as a marketplace distribution channel for the ClearCell FX1 System, making the product available to a broader range of buyers including smaller research facilities and individual researchers through the LabX e-commerce platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of CELLSEARCH, the first and only FDA-cleared CTC enumeration test. Direct competitor to Biolidics' ClearCell FX1 in circulating tumor cell enrichment from blood, targeting oncology research and clinical diagnostics laboratories.

TypeDirect peer
Description

UK-listed developer of the Parsortix system, a label-free microfluidic CTC isolation platform. Direct technical competitor to Biolidics' ClearCell FX1, also addressing the liquid biopsy market with a size- and deformity-based CTC capture approach.

TypeDirect peer
Description

US-based developer of the RareCyte platform for CTC identification and retrieval from blood. Comparable to Biolidics in offering instrumentation for intact CTC isolation for downstream oncology research and companion diagnostic applications.

TypeDirect peer
Description

Developer of a CTC liquid biopsy platform for characterizing circulating tumor cells from blood. Comparable to Biolidics in serving oncology researchers and biopharma with CTC-based analysis tools.

TypeDirect peer
Description

US-based liquid biopsy company offering CTC and ctDNA-based oncology diagnostics. Smaller, single-platform peer comparable to Biolidics in targeting community oncology and pathology labs with blood-based cancer tests.

TypeDirect peer
Description

Developer of CTC isolation devices (ScreenCell products) for cancer research and liquid biopsy applications. Comparable niche player offering filtration-based CTC enrichment tools to research and clinical labs.

TypeBroad incumbent
Description

US-based leader in liquid biopsy, offering NGS-based ctDNA tests (Guardant360, Reveal) for oncology. While focused on ctDNA rather than CTCs, it is a broad incumbent defining the competitive landscape for blood-based cancer diagnostics that Biolidics operates in.

TypeBroad incumbent
Description

Developer of cell-free DNA-based oncology tests (Signatera MRD) and reproductive health diagnostics. Larger commercial-stage incumbent in the liquid biopsy space where Biolidics competes for oncology lab budgets.

TypeBroad incumbent
Description

US-based diagnostics company (Cologuard, Oncotype DX, OncoExTra) with a growing liquid biopsy franchise. Broad incumbent in oncology diagnostics whose expanding portfolio shapes demand for blood-based cancer tests.

10CytoLumina Technologies
TypeEmerging player
Description

Early-stage developer of microfluidic CTC isolation technologies spun out of academic research. Emerging player addressing overlapping niche applications in CTC enrichment for cancer diagnostics and research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biolidics

Cancer Diagnostics Medical Devicesbiolidics.com

Biolidics (Embracing Future Holdings Limited, SGX: 8YY) is a Singapore-based medical device company that develops and commercializes the ClearCell FX1 System, an FDA-cleared IVD device using its patented CTChip FR1 microfluidic biochip to enrich circulating tumor cells from blood for pathology laboratories and oncology researchers.

What Biolidics does

Biolidics is the operating brand of Embracing Future Holdings Limited (EFH), a Singapore-incorporated, SGX-listed (ticker: 8YY) medical device company founded in 2009 that develops and commercializes the ClearCell FX1 System, a fully automated IVD medical device for label-free separation and enrichment of circulating tumor cells (CTCs) from blood. The system is built around the proprietary, patented CTChip FR1 microfluidic biochip, which isolates wholly intact and viable CTCs in liquid suspension that can be transferred to standard laboratory formats such as glass slides and microtiter plates for integration with routine pathology workflows. The company is headquartered at 122 Emerald Hill Road, Singapore, and serves pathology laboratories and oncology healthcare providers engaged in cancer diagnostics, liquid biopsy, and CTC research.

The company monetizes through hardware sales of the ClearCell FX1 System under a quote-based pricing model that is not publicly disclosed. Its go-to-market combines direct enterprise sales via a Request-for-Quotation channel on the corporate website with marketplace distribution through LabX, enabling access to both large laboratories and smaller research buyers. Beyond the oncology diagnostics franchise, EFH has publicly disclosed a strategic intent to diversify into technology-enabled lifestyle businesses, including Multi-Channel Networks, live streaming social e-commerce, and Esports-related operations. The company has raised approximately $11.7M in disclosed funding across a 2013 Series A led by Vertex Ventures and a 2018 round, and acquired Biomedical Laboratory in March 2020 for approximately $2.6M.

Biolidics firmographics

Firmographics
Name
Biolidics
Legal name
Embracing Future Holdings Limited
Website
https://biolidics.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Biolidics (Embracing Future Holdings Limited, SGX: 8YY) is a Singapore-based medical device company that develops and commercializes the ClearCell FX1 System, an FDA-cleared IVD device using its patented CTChip FR1 microfluidic biochip to enrich circulating tumor cells from blood for pathology laboratories and oncology researchers.
Ownership category
akta.pro rank

Biolidics industry classification

Industry
Product category
Cancer Diagnostics Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Circulating tumor cell enrichment
  • Liquid biopsy diagnostics
  • Microfluidic biochip technology
  • IVD medical devices
  • Cancer diagnostics

Where Biolidics is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

Biolidics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

  1. Medical Device Sales: Sale of the ClearCell FX1 System, a fully automated IVD medical device for CTC enrichment. Revenue generated through direct sales to laboratories and healthcare facilities, as well as through marketplace distribution.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing for ClearCell FX1 System

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Biolidics product offering

Product offering

Core offering

Biolidics develops and commercializes the ClearCell FX1 System, a fully automated in-vitro diagnostic (IVD) medical device that separates and enriches circulating tumor cells (CTCs) from blood samples using a patented microfluidic biochip (CTChip FR1). The system enables label-free, viable and intact CTC isolation that can be transferred to standard laboratory formats such as glass slides and microtiter plates for downstream pathology and oncology workflows.

Product overview

Biolidics offers a focused diagnostic product portfolio centered on the ClearCell® FX1 System, a fully automated IVD medical device for circulating tumor cell (CTC) enrichment. The system incorporates the proprietary CTChip® FR1 microfluidic biochip to achieve label-free separation of viable and intact cancer cells from blood samples. The isolated CTCs are collected in liquid suspension and can be transferred to standard laboratory formats such as glass slides and microtiter plates for integration with routine pathology workflows.

Differentiator

Problem solved

Functional benefit

Companies that use Biolidics

Customer profile

Segments2 records

Ideal customer profiles2 records

Biolidics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Biolidics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • LabXminorChannel Partner/ Reseller/ DistributorLabX serves as a marketplace distribution channel for the ClearCell FX1 System, making the product available to a broader range of buyers including smaller research facilities and individual researchers through the LabX e-commerce platform.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Biolidics competitors and assessment

Company assessment

Direct peers

  • Menarini Silicon Biosystems: Developer of CELLSEARCH, the first and only FDA-cleared CTC enumeration test. Direct competitor to Biolidics' ClearCell FX1 in circulating tumor cell enrichment from blood, targeting oncology research and clinical diagnostics laboratories.
  • ANGLE plc: UK-listed developer of the Parsortix system, a label-free microfluidic CTC isolation platform. Direct technical competitor to Biolidics' ClearCell FX1, also addressing the liquid biopsy market with a size- and deformity-based CTC capture approach.
  • RareCyte: US-based developer of the RareCyte platform for CTC identification and retrieval from blood. Comparable to Biolidics in offering instrumentation for intact CTC isolation for downstream oncology research and companion diagnostic applications.
  • Epic Sciences: Developer of a CTC liquid biopsy platform for characterizing circulating tumor cells from blood. Comparable to Biolidics in serving oncology researchers and biopharma with CTC-based analysis tools.
  • Biocept: US-based liquid biopsy company offering CTC and ctDNA-based oncology diagnostics. Smaller, single-platform peer comparable to Biolidics in targeting community oncology and pathology labs with blood-based cancer tests.
  • ScreenCell: Developer of CTC isolation devices (ScreenCell products) for cancer research and liquid biopsy applications. Comparable niche player offering filtration-based CTC enrichment tools to research and clinical labs.

Broad incumbents

  • Guardant Health: US-based leader in liquid biopsy, offering NGS-based ctDNA tests (Guardant360, Reveal) for oncology. While focused on ctDNA rather than CTCs, it is a broad incumbent defining the competitive landscape for blood-based cancer diagnostics that Biolidics operates in.
  • Natera: Developer of cell-free DNA-based oncology tests (Signatera MRD) and reproductive health diagnostics. Larger commercial-stage incumbent in the liquid biopsy space where Biolidics competes for oncology lab budgets.
  • Exact Sciences: US-based diagnostics company (Cologuard, Oncotype DX, OncoExTra) with a growing liquid biopsy franchise. Broad incumbent in oncology diagnostics whose expanding portfolio shapes demand for blood-based cancer tests.

Emerging players

  • CytoLumina Technologies: Early-stage developer of microfluidic CTC isolation technologies spun out of academic research. Emerging player addressing overlapping niche applications in CTC enrichment for cancer diagnostics and research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Biolidics social profiles

Digital presence

Biolidics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biolidics leadership team

Management profile

Number of profiles

Profiles3 records

Biolidics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biolidics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biolidics

What does Biolidics do?

Biolidics develops and commercializes the ClearCell FX1 System, a fully automated in-vitro diagnostic (IVD) medical device that separates and enriches circulating tumor cells (CTCs) from blood samples using a patented microfluidic biochip (CTChip FR1). The system enables label-free, viable and intact CTC isolation that can be transferred to standard laboratory formats such as glass slides and microtiter plates for downstream pathology and oncology workflows.

Is Biolidics a public or private company?

Biolidics is a public company. It is classified as public and is currently operating.

When was Biolidics founded?

Biolidics was founded in 2009. It employs 11 to 50 people.

Where is Biolidics based?

Biolidics is headquartered in Singapore, Singapore, in the Asia region.

How does Biolidics make money?

One revenue line is on record: medical Device Sales.

Who are Biolidics's main competitors?

Direct peers on record are Menarini Silicon Biosystems, ANGLE plc, RareCyte, Epic Sciences, Biocept and ScreenCell. Broad incumbents are Guardant Health, Natera and Exact Sciences. CytoLumina Technologies is listed as an emerging player.

Does Biolidics have an API?

No public API is recorded for Biolidics.

What industry is Biolidics in?

Biolidics's product category is Cancer Diagnostics Medical Devices. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestSingapore's Diagnostic Playbook: Capitalizing on U.S. Federal Funding CutsU.S. NIH funding cuts to $27 billion from $47 billion are creating a $100 billion opportunity for Singapore's diagnostic firms. The article highlights GenScript, Biolidics, and VisEn Medical as undervalued targets, with GenScript trading at 12x forward earnings versus peers at 20x+. It recommends a two-pronged investment strategy targeting a 15% return in 12–18 months.The Business TimesSGX queries Biolidics on A*Star licence dealSGX queried Biolidics on a licence agreement with A*Star's Accelerate Technologies for Covid-19 spike/ACE2 antibody detection. The five-year deal, entered July 9, covers the agency's technology. SGX also asked about the trading halt and announcement timing.THE BUSINESS TIMESSingapore shares close 0.6% downSingapore's Straits Times Index fell 0.6% to 2,652.65 on Thursday, with 23 of 30 listed stocks losing ground. OCBC, DBS, and Capitaland Mall Trust led losses, while Biolidics surged 32.3% on a new partnership. Trading was thin, with volumes at S$1.09 billion.THE BUSINESS TIMESBiolidics calls off US sale of Covid-19 test kits, to develop new kit with Aytu BioScienceBiolidics terminated its US distribution deal for Covid-19 antibody test kits with Aytu BioScience, citing increased competition. It signed a non-binding LOI to jointly develop a new test kit for broader use outside clinical settings. The company will withdraw its EUA application and continue selling kits in other markets.The Straits TimesSingapore stock watch: SIA, SGX, SIIC Environment, Biolidics, Tee InternationalSingapore Airlines cut US route capacity and offered fee waivers, while SGX announced a $5 million care package. SIIC Environment started a wastewater plant in China, Biolidics raised $3.1 million via share placement, and Tee International tightened governance. HRnetGroup plans to use flexible staffing and M&A amid Covid-19.PR NewswireIncellDx Signs Liquid Biopsy Distribution Agreement with Singapore-based Biolidics, Inc.IncellDx, Inc. and Biolidics signed a Distribution Agreement on December 18, 2019, granting Biolidics rights to distribute the IncellDx bioINK® PD-L1 CTC Core Kit alongside its ClearCell® FX1 System for liquid biopsy applications. The bioINK® kit enables highly sensitive quantification of protein and mRNA expression on circulating tumor cells at single-cell resolution for microfluidic chips, with a proprietary fixation method that preserves genetic material for downstream sequencing. IncellDx CEO Bruce Patterson stated the agreement covers the first of several cancer-specific bioINK® kits targeting breast, lung, urologic cancers, and sarcomas, expanding the company's liquid biopsy reagent technology into new markets.PR NewswireClearbridge BioMedics dehnt Verfügbarkeit vom ClearCell(R) FX1 System die EMEA- und APAC-Regionen ausClearbridge BioMedics announced the expansion of its ClearCell® FX1 System availability to the EMEA and APAC regions through partnerships with twelve new distributors. This move supplements the system's existing direct availability in the USA, which has been operational since its 2015 commercial launch. The company plans to make the automated liquid biopsy device accessible in 26 additional countries via this international distributor network.PR NewswireClearbridge BioMedics amplía la disponibilidad de ClearCell(R) FX1 en las regiones EMEA y APACClearbridge BioMedics announced the expansion of its ClearCell FX1 liquid biopsy platform to the EMEA and APAC regions through twelve new distribution partnerships. The platform, which enriches circulating tumor cells from blood samples, will now be available in 26 new countries, with products manufactured in Singapore. The new distributor network includes partners across Europe, Asia, and the Middle East covering countries such as Germany, Spain, South Korea, Vietnam, and Russia.PR NewswireClearbridge BioMedics se une como primer socio asiático del consorcio CANCER-IDClearbridge BioMedics announced on October 2, 2017 that it has joined CANCER-ID, an international public-private consortium focused on establishing standardized protocols for blood-based biomarkers and their clinical validation. The company, based in Singapore, becomes the consortium's first Asian partner among 38 members from 14 countries, contributing its ClearCell® FX System, a label-free microfluidic platform for enriching and isolating circulating tumor cells (CTCs) from blood samples for liquid biopsy applications. Clearbridge BioMedics stated the partnership aims to accelerate adoption of CTC-based diagnostics in clinical settings, ultimately improving cancer patient management and outcomes.PR NewswireBGI and Clearbridge BioMedics Partner to Develop China CTC Liquid Biopsy Market towards Precision MedicineBGI, the world's largest genomics organization, has signed a partnership agreement with Singapore-based oncology diagnostics company Clearbridge BioMedics to develop the CTC liquid biopsy market in China, covering Mainland China, Hong Kong, and Macao. Under the agreement, BGI will become the sole distributor and marketer of Clearbridge's ClearCell FX1 solution in China, while both companies will collaborate to develop integrated clinical products for cancer diagnostics using CTC enrichment technology combined with genomic analysis. The collaboration focuses on major cancer types prevalent in China, including lung, breast, and liver cancer, with the aim of accelerating precision medicine adoption in the region.